Imaging-guided radiofrequency ablation of solid renal tumors

M. A. Farrell, W. J. Charboneau, D. S. DiMarco, G. K. Chow, H. Zincke, Matthew R Callstrom, B. D. Lewis, R. A. Lee, C. C. Reading

Research output: Contribution to journalArticle

232 Citations (Scopus)

Abstract

OBJECTIVE. We performed a retrospective review of imaging-guided radiofrequency ablation of solid renal tumors. MATERIALS AND METHODS. Since May 2000, 35 tumors in 20 patients have been treated with radiofrequency ablation. The size range of treated tumors was 0.9-3.6 cm (mean, 1.7 cm). Reasons for patient referrals were a prior partial or total nephrectomy (nine patients), a comorbidity excluding nephrectomy or partial nephrectomy (10 patients), or a treatment alterative to nephron-sparing surgery (one patient who refused surgery). Tumors were classified as exophytic, intraparenchymal, or central. Sixteen patients had 31 lesions that showed serial growth on CT or MR imaging. Of these 16 patients, four patients with 10 lesions had a history of renal cell carcinoma, and two patients with 11 lesions had a history of von Hippel-Lindau disease. Four patients had incidental solid masses, two of which were biopsied and shown to represent renal cell carcinoma, and the remaining two masses were presumed malignant on the basis of imaging features. Successful ablation was regarded as any lesion showing less than 10 H of contrast enhancement on CT or no qualitative evidence of enhancement after IV gadolinium contrast-enhanced MR imaging. RESULTS. Of the 35 tumors, 22 were exophytic and 13 were intraparenchymal. Twenty-seven of the 35 were treated percutaneously using either sonography (n = 22) or CT (n = 5). Two patients had eight tumors treated intraoperatively using sonography. Patients were followed up with contrast-enhanced CT (n = 18), MR imaging (n = 5), or both (n = 5) with a follow-up range of 1-23 months (mean, 9 months). No residual or recurrent tumor and no major side effects were seen. CONCLUSION. Preliminary results with radiofrequency ablation of exophytic and intraparenchymal renal tumors are promising. Radiofrequency ablation is not associated with significant side effects. Further follow-up is necessary to determine the long-term efficacy of radiofrequency ablation.

Original languageEnglish (US)
Pages (from-to)1509-1513
Number of pages5
JournalAmerican Journal of Roentgenology
Volume180
Issue number6
StatePublished - Jun 1 2003

Fingerprint

Kidney
Neoplasms
Nephrectomy
Renal Cell Carcinoma
Ultrasonography
von Hippel-Lindau Disease
Nephrons
Gadolinium
Comorbidity
Referral and Consultation
Growth

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Farrell, M. A., Charboneau, W. J., DiMarco, D. S., Chow, G. K., Zincke, H., Callstrom, M. R., ... Reading, C. C. (2003). Imaging-guided radiofrequency ablation of solid renal tumors. American Journal of Roentgenology, 180(6), 1509-1513.

Imaging-guided radiofrequency ablation of solid renal tumors. / Farrell, M. A.; Charboneau, W. J.; DiMarco, D. S.; Chow, G. K.; Zincke, H.; Callstrom, Matthew R; Lewis, B. D.; Lee, R. A.; Reading, C. C.

In: American Journal of Roentgenology, Vol. 180, No. 6, 01.06.2003, p. 1509-1513.

Research output: Contribution to journalArticle

Farrell, MA, Charboneau, WJ, DiMarco, DS, Chow, GK, Zincke, H, Callstrom, MR, Lewis, BD, Lee, RA & Reading, CC 2003, 'Imaging-guided radiofrequency ablation of solid renal tumors', American Journal of Roentgenology, vol. 180, no. 6, pp. 1509-1513.
Farrell MA, Charboneau WJ, DiMarco DS, Chow GK, Zincke H, Callstrom MR et al. Imaging-guided radiofrequency ablation of solid renal tumors. American Journal of Roentgenology. 2003 Jun 1;180(6):1509-1513.
Farrell, M. A. ; Charboneau, W. J. ; DiMarco, D. S. ; Chow, G. K. ; Zincke, H. ; Callstrom, Matthew R ; Lewis, B. D. ; Lee, R. A. ; Reading, C. C. / Imaging-guided radiofrequency ablation of solid renal tumors. In: American Journal of Roentgenology. 2003 ; Vol. 180, No. 6. pp. 1509-1513.
@article{36f36bbe5275474aa9362b14599f61c1,
title = "Imaging-guided radiofrequency ablation of solid renal tumors",
abstract = "OBJECTIVE. We performed a retrospective review of imaging-guided radiofrequency ablation of solid renal tumors. MATERIALS AND METHODS. Since May 2000, 35 tumors in 20 patients have been treated with radiofrequency ablation. The size range of treated tumors was 0.9-3.6 cm (mean, 1.7 cm). Reasons for patient referrals were a prior partial or total nephrectomy (nine patients), a comorbidity excluding nephrectomy or partial nephrectomy (10 patients), or a treatment alterative to nephron-sparing surgery (one patient who refused surgery). Tumors were classified as exophytic, intraparenchymal, or central. Sixteen patients had 31 lesions that showed serial growth on CT or MR imaging. Of these 16 patients, four patients with 10 lesions had a history of renal cell carcinoma, and two patients with 11 lesions had a history of von Hippel-Lindau disease. Four patients had incidental solid masses, two of which were biopsied and shown to represent renal cell carcinoma, and the remaining two masses were presumed malignant on the basis of imaging features. Successful ablation was regarded as any lesion showing less than 10 H of contrast enhancement on CT or no qualitative evidence of enhancement after IV gadolinium contrast-enhanced MR imaging. RESULTS. Of the 35 tumors, 22 were exophytic and 13 were intraparenchymal. Twenty-seven of the 35 were treated percutaneously using either sonography (n = 22) or CT (n = 5). Two patients had eight tumors treated intraoperatively using sonography. Patients were followed up with contrast-enhanced CT (n = 18), MR imaging (n = 5), or both (n = 5) with a follow-up range of 1-23 months (mean, 9 months). No residual or recurrent tumor and no major side effects were seen. CONCLUSION. Preliminary results with radiofrequency ablation of exophytic and intraparenchymal renal tumors are promising. Radiofrequency ablation is not associated with significant side effects. Further follow-up is necessary to determine the long-term efficacy of radiofrequency ablation.",
author = "Farrell, {M. A.} and Charboneau, {W. J.} and DiMarco, {D. S.} and Chow, {G. K.} and H. Zincke and Callstrom, {Matthew R} and Lewis, {B. D.} and Lee, {R. A.} and Reading, {C. C.}",
year = "2003",
month = "6",
day = "1",
language = "English (US)",
volume = "180",
pages = "1509--1513",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "6",

}

TY - JOUR

T1 - Imaging-guided radiofrequency ablation of solid renal tumors

AU - Farrell, M. A.

AU - Charboneau, W. J.

AU - DiMarco, D. S.

AU - Chow, G. K.

AU - Zincke, H.

AU - Callstrom, Matthew R

AU - Lewis, B. D.

AU - Lee, R. A.

AU - Reading, C. C.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - OBJECTIVE. We performed a retrospective review of imaging-guided radiofrequency ablation of solid renal tumors. MATERIALS AND METHODS. Since May 2000, 35 tumors in 20 patients have been treated with radiofrequency ablation. The size range of treated tumors was 0.9-3.6 cm (mean, 1.7 cm). Reasons for patient referrals were a prior partial or total nephrectomy (nine patients), a comorbidity excluding nephrectomy or partial nephrectomy (10 patients), or a treatment alterative to nephron-sparing surgery (one patient who refused surgery). Tumors were classified as exophytic, intraparenchymal, or central. Sixteen patients had 31 lesions that showed serial growth on CT or MR imaging. Of these 16 patients, four patients with 10 lesions had a history of renal cell carcinoma, and two patients with 11 lesions had a history of von Hippel-Lindau disease. Four patients had incidental solid masses, two of which were biopsied and shown to represent renal cell carcinoma, and the remaining two masses were presumed malignant on the basis of imaging features. Successful ablation was regarded as any lesion showing less than 10 H of contrast enhancement on CT or no qualitative evidence of enhancement after IV gadolinium contrast-enhanced MR imaging. RESULTS. Of the 35 tumors, 22 were exophytic and 13 were intraparenchymal. Twenty-seven of the 35 were treated percutaneously using either sonography (n = 22) or CT (n = 5). Two patients had eight tumors treated intraoperatively using sonography. Patients were followed up with contrast-enhanced CT (n = 18), MR imaging (n = 5), or both (n = 5) with a follow-up range of 1-23 months (mean, 9 months). No residual or recurrent tumor and no major side effects were seen. CONCLUSION. Preliminary results with radiofrequency ablation of exophytic and intraparenchymal renal tumors are promising. Radiofrequency ablation is not associated with significant side effects. Further follow-up is necessary to determine the long-term efficacy of radiofrequency ablation.

AB - OBJECTIVE. We performed a retrospective review of imaging-guided radiofrequency ablation of solid renal tumors. MATERIALS AND METHODS. Since May 2000, 35 tumors in 20 patients have been treated with radiofrequency ablation. The size range of treated tumors was 0.9-3.6 cm (mean, 1.7 cm). Reasons for patient referrals were a prior partial or total nephrectomy (nine patients), a comorbidity excluding nephrectomy or partial nephrectomy (10 patients), or a treatment alterative to nephron-sparing surgery (one patient who refused surgery). Tumors were classified as exophytic, intraparenchymal, or central. Sixteen patients had 31 lesions that showed serial growth on CT or MR imaging. Of these 16 patients, four patients with 10 lesions had a history of renal cell carcinoma, and two patients with 11 lesions had a history of von Hippel-Lindau disease. Four patients had incidental solid masses, two of which were biopsied and shown to represent renal cell carcinoma, and the remaining two masses were presumed malignant on the basis of imaging features. Successful ablation was regarded as any lesion showing less than 10 H of contrast enhancement on CT or no qualitative evidence of enhancement after IV gadolinium contrast-enhanced MR imaging. RESULTS. Of the 35 tumors, 22 were exophytic and 13 were intraparenchymal. Twenty-seven of the 35 were treated percutaneously using either sonography (n = 22) or CT (n = 5). Two patients had eight tumors treated intraoperatively using sonography. Patients were followed up with contrast-enhanced CT (n = 18), MR imaging (n = 5), or both (n = 5) with a follow-up range of 1-23 months (mean, 9 months). No residual or recurrent tumor and no major side effects were seen. CONCLUSION. Preliminary results with radiofrequency ablation of exophytic and intraparenchymal renal tumors are promising. Radiofrequency ablation is not associated with significant side effects. Further follow-up is necessary to determine the long-term efficacy of radiofrequency ablation.

UR - http://www.scopus.com/inward/record.url?scp=0037498194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037498194&partnerID=8YFLogxK

M3 - Article

VL - 180

SP - 1509

EP - 1513

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 6

ER -